Merrimack Pharmaceuticals, Inc.

Immunogen, Inc.

Neeraj Kohli

Alexey Alexandrovich Lugovskoy

Eric Krauland

Michael Feldhaus

Ulrik Bjerl Nielsen

Raghida Bukhalid

Jonathan Basil Fitzgerald

Sharlene Adams

Jeffrey David Kearns

Lihui Xu

Jason Baum

Bryan Johnson

Anne Richard

Olga Ab

Thomas D Chittenden

Julianto Setiady

Anne King

Brian Harms

Melissa Geddie

William George Roach

Stephen Su

Adnan Abu-Yousif

The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR&#x3b1;) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR&#x3b1; and modulate FR&#x3b1; activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR&#x3b1; and modulates FR&#x3b1; activity.

Biparatopic FR-alpha antibodies and immunoconjugates

Biparatopic FR-&#x3b1; antibodies and immunoconjugates

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies

Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies

Provided herein are tandem Fcs and tandem Fc antibodies ('TFcAs'), e.g., tandem Fc bispecific antibodies ('TFcBAs'), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.

ANTI-C-MET tandem Fc bispecific antibodies

Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Growing community of inventors

Brighton, MA, United States of America

Neeraj Kohli